ICP
NVCR icon

Interchange Capital Partners’s NovoCure NVCR Stock Holding History

Interchange Capital Partners’s Portfolio NVCR Stock Details NVCR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-11,851
Closed -$153K – 418
2025
Q4 		$153K Buy
+11,851
New +$152K 0.03% 410
2021
Q1 		– Sell
-183
Closed -$31K – 810
2020
Q4 		$31K Buy
+183
New +$25K 0.02% 510

Other funds holding NVCR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
QCM
Quantinno Capital Management New York $59.9B AUM 28.07% 1-Year Est. Return

Interchange Capital Partners's NVCR Position: Q1 2026 in Review

Interchange Capital Partners sold out of NovoCure (NVCR) in Q1 2026, closing a stake of 11,851 shares — an estimated $153K sold.

Interchange Capital Partners first reported a position in NVCR in Q4 2020 and held it in 2 quarters. The position peaked at $153K in Q4 2025. 222 funds tracked by Wall St. Rank hold NVCR as of Q1 2026.

  • Interchange Capital Partners reported no remaining NovoCure position as of Q1 2026 after selling out during the quarter.
  • Interchange Capital Partners sold 11,851 NovoCure shares in Q1 2026, an estimated $153K.
  • Interchange Capital Partners first reported a position in NovoCure in Q4 2020 and held it in 2 quarters.
  • Interchange Capital Partners's NovoCure position peaked at $153K in Q4 2025.
  • 222 funds tracked by Wall St. Rank held NovoCure as of Q1 2026.

Based on Interchange Capital Partners's 13F filing for Q1 2026, filed 24 Apr 2026.